Janux Therapeutics Inc

JANXNASDAQ · USD
17.38USD+0.37 (+2.18%)
435

Janux Therapeutics Inc (JANX) Option Chain

As of September 21, 2026, Janux Therapeutics Inc is trading at $17.38, a +2.18% change from the previous close. The nearest expiration is Oct 16, 2026. Implied volatility is 58.5%. IV Rank is 11%.

Read more

Tracking the JANX option chain helps you see every strike and expiry on Janux Therapeutics Inc in one view, so you can quickly identify the contracts that fit your thesis and your risk. Janux Therapeutics Inc's option chain lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of JANX options activity at a glance. Use our scanner to monitor the JANX option chain in real time and filter for the JANX options trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For JANX stock options, the chain shows side-by-side call and put data, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading the JANX option chain effectively means looking beyond the last price — implied volatility by strike, volume-to-open-interest ratios, and bid-ask spreads all tell you where JANX stock options are being actively traded and where they are not.

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells.

In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.

Credit spreads, long calls, iron condors, calendar trades — every strategy starts with the same raw material: a clean, complete option chain. Our scanner pulls Janux Therapeutics Inc's full chain across every expiry, highlights the most liquid strikes, and lets you screen JANX options by the metrics that matter, from IV skew to volume surges. Stop scrolling through endless rows of JANX stock options — let the full option chain come to you, pre-filtered and ready to trade.

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV percentile15.48% Subdued
  • Market cap (M$)1,040
  • 52 weeks high-51.87%
  • 52 weeks low40.35%
  • Analyst recommendationStrong Buy
    1.50
  • Target price$31.53
    81.42% above the current stock price
  • Dividend
  • Payout ratio
  • Earnings date2026-11-05
  • P/E
  • Future P/E
  • EPS (ttm)-1.64
  • EPS growth next 5 years-22.06%

As of September 21, 2026

2026-10-16
5 strikes
Default
CALLsPUTs
Prob. OTM %Open InterestVolumeExtrinsic ValueIntrinsic ValueBidAskStrikeMoneyness %BidAskIntrinsic ValueExtrinsic ValueVolumeOpen InterestProb. OTM %
2.4700-0.284.882.506.7012.50-26.510.600.000.600097.53
22.151400.102.380.554.4015.00-11.821.000.001.000077.85
59.686200.680.000.500.8517.50+2.880.302.450.121.2504940.32
86.906110.180.000.100.2520.00+17.581.454.702.620.4501413.10
97.10312.250.002.2522.50+32.283.707.405.120.43002.90

As of September 21, 2026

Scan the full option chain in one place

Browse the full JANX option chain across every strike and expiration, filter by IV, volume, and open interest, and evaluate your trade without switching tools.

Start your 14-day free trial